Navigation Links
Medarex Announces Primary Endpoint Achieved in MDX-1100 Anti-IP-10 Antibody Phase 2 Trial for Rheumatoid Arthritis
Date:5/14/2009

re results, performance or achievements expressed or implied by such statements. Medarex disclaims, however, any intent or obligation to update these forward-looking statements. Risks and uncertainties include risks associated with product discovery and development of MDX-1100, uncertainties related to the outcome of clinical trials, slower than expected rates of patient recruitment, unforeseen safety issues resulting from the administration of antibody products in patients, uncertainties related to product manufacturing, as well as risks detailed from time to time in Medarex's public disclosure filings with the U.S. Securities and Exchange Commission (SEC), including its Annual Report on Form 10-K for the fiscal year ended December 31, 2008 its quarterly reports on Form 10-Q. There can be no assurance that such development efforts will succeed or that developed products will receive required regulatory clearance or that, even if such regulatory clearance were received, such products would ultimately achieve commercial success. Copies of Medarex's public disclosure filings are available from its investor relations department.

Medarex(R), the Medarex logo, UltiMAb(R) and HuMAb(TM) are trademarks of Medarex, Inc. All rights are reserved.


'/>"/>
SOURCE Medarex, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Medarex Announces Allowance of Investigational New Drug Applications for Wholly Owned Fully Human Anti-CD19 Antibody, MDX-1342
2. Medarex to Receive Milestone Payment from Amgen
3. Medarex Announces Ipilimumab Program Continues to Move Forward
4. Medarex Reports Interim Data from Ongoing Ipilimumab Combination Phase 1 Studies in Prostate Cancer at American Association for Cancer Research Meeting
5. Medarex Announces Presentations at Annual Meeting of the American Society of Clinical Oncology
6. Medarex Announces Initiation of Phase 2 Clinical Trials for the Treatment of Ulcerative Colitis and Rheumatoid Arthritis
7. Medarex Highlights Strength in Antibody Development and Underlying Pipeline Strategy at R&D Day Event in New York City
8. Medarex Announces Allowance of Investigational New Drug Application for Wholly-Owned Fully Human Anti-PD-L1 Antibody, MDX-1105
9. Medarex Announces Initiation of Phase 2 Clinical Development Program for the Treatment of Lupus
10. Medarex Announces Presentations at the 33rd Congress of the European Society for Medical Oncology
11. Medarex Receives Milestone Payment from Pfizer for Investigational New Drug Application Filing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... Calif. , Aug. 3, 2015  Depomed, Inc. ... commented on Horizon Pharma plc,s (NASDAQ: HZNP ) ... Board of Directors ("Depomed Board") set a record date ... meeting. The Depomed Board will review ... request is received today and contains the information required ...
(Date:8/3/2015)... , Aug. 3, 2015  Dr. ... Orthopaedic & Spine Center today, providing ... manage their chronic pain through psychological counseling and ... is a Fellowship-trained, certified medical psychologist with an ... His vast experience ranges from assessment and treatment ...
(Date:8/3/2015)... 3, 2015 /OFF HOLD ... LLC, PIV757417 The following release: "Biotech Advancements Coupled ... Products & Treatments for Critical-Care Patients With Severe ... 3 Aug 2015 12:30 GMT Cooperative ... surgical research and top-tier universities for identifying biotech ...
Breaking Medicine Technology:Depomed Comments on Horizon Pharma Announcement 2Depomed Comments on Horizon Pharma Announcement 3Depomed Comments on Horizon Pharma Announcement 4Depomed Comments on Horizon Pharma Announcement 5Depomed Comments on Horizon Pharma Announcement 6Orthopaedic & Spine Center Introduces New Pain Psychologist 2/OFF HOLD OFF HOLD OFF HOLD -- FN Media Group LLC/ 2/OFF HOLD OFF HOLD OFF HOLD -- FN Media Group LLC/ 3/OFF HOLD OFF HOLD OFF HOLD -- FN Media Group LLC/ 4/OFF HOLD OFF HOLD OFF HOLD -- FN Media Group LLC/ 5/OFF HOLD OFF HOLD OFF HOLD -- FN Media Group LLC/ 6
(Date:8/3/2015)... ... August 03, 2015 , ... Bayer has agreed to pay $56.9 million to ... a claimant alleged to have suffered an arterial blood clot including stroke and heart ... Yasmin and Ocella, has been ongoing for well-over five years. In 2009, lawsuits filed ...
(Date:8/3/2015)... ... August 03, 2015 , ... Novation, ... Genelex to offer pharmacogenetic lab testing and precision medicine solutions that can help ... , Annually, more than 8.6 million adverse drug events are reported in ...
(Date:8/3/2015)... ... August 03, 2015 , ... Social impact organization’s #HelpOneHelpMany ... 2015 – Since winning a South by Southwest® (SXSW®) Interactive Innovation Award in ... whose mission is to develop technology for the sake of humanity – continues ...
(Date:8/3/2015)... ... August 03, 2015 , ... ... it’s new program “Designing Secure Healthcare Systems” This three-day, highly interactive and ... from healthcare organizations with access to the tactics, techniques and practices required to ...
(Date:8/3/2015)... ... August 03, 2015 , ... From 2006-2017 the number of ... to market research compiled for the National Association of Dental Laboratories ( NADL ... Bureau of Labor Statistics. As the number of dental laboratories decreases, dentists will ...
Breaking Medicine News(10 mins):Health News:Bayer Agrees To Settle Yaz Aterial Blood Clot Lawsuits 2Health News:Novation Awards Genelex First Group Purchasing Agreement for Pharmacogenetic Testing and Precision Medicine Software 2Health News:Novation Awards Genelex First Group Purchasing Agreement for Pharmacogenetic Testing and Precision Medicine Software 3Health News:Not Impossible Earns Top Awards for Technologies Benefiting Humanity 2Health News:Not Impossible Earns Top Awards for Technologies Benefiting Humanity 3Health News:Not Impossible Earns Top Awards for Technologies Benefiting Humanity 4Health News:Sensato and Divurgent are pleased to announce the development of it’s new program “Designing Secure Healthcare Systems” 2Health News:Sensato and Divurgent are pleased to announce the development of it’s new program “Designing Secure Healthcare Systems” 3Health News:Sensato and Divurgent are pleased to announce the development of it’s new program “Designing Secure Healthcare Systems” 4Health News:Dental Association Announces Impending Reduction of Dental Laboratories Could Impact Dentists 2Health News:Dental Association Announces Impending Reduction of Dental Laboratories Could Impact Dentists 3
... the Americans with Disabilities Act, there is finally a ... are in compliance. "This is designed to meet ... not necessarily a techie," explains Denis Anson, director of ... Misericordia University in Dallas, Pennsylvania, and the kit,s developer. ...
... climate change as a public health problem seems to ... members of the publiceven some who don,t generally believe ... George Mason University,s Center for Climate Change Communication (4C). ... the United States of people,s reactions to a public ...
... Owusu, MD, associate professor at Case Western Reserve University ... School,s primary affiliate, has received nearly $500,000 from Susan ... three-year study aimed at improving outcomes for older women ... life expectancy coupled with aging as a risk factor ...
... SUNDAY, July 18 (HealthDay News) -- Wouldn,t it be nice ... skin patch instead of a shot? Experiments in mice ... deliver the influenza vaccine may someday be a viable alternative ... millimeter in length, or about half the thickness of a ...
... By Jenifer Goodwin HealthDay Reporter , FRIDAY, July ... new research shows the long-term cost of wearing them is ... brands. , , Along with aching feet and a variety ... the anatomy of the calf muscles and tendons, according to ...
... organizationrecognized the contributions and work to the field ... 57th Annual Meeting in Salt Lake City. Several ... that SNM members play in advancing the diagnosis ... conditions. "Nuclear medicine researchers, physicians and educators ...
Cached Medicine News:Health News:Toolkit allows anyone to test for ADA compliance 2Health News:Toolkit allows anyone to test for ADA compliance 3Health News:When climate change becomes a health issue, are people more likely to listen? 2Health News:Susan G. Komen awards Case Western Reserve nearly $500,000 to study breast cancer in older women 2Health News:Susan G. Komen awards Case Western Reserve nearly $500,000 to study breast cancer in older women 3Health News:Flu Vaccine Via Skin Patch Shows Promise in Mice 2Health News:Flu Vaccine Via Skin Patch Shows Promise in Mice 3Health News:Those To-Die-For High Heels May Alter Anatomy 2Health News:Those To-Die-For High Heels May Alter Anatomy 3Health News:SNM honors outstanding contributors 2Health News:SNM honors outstanding contributors 3Health News:SNM honors outstanding contributors 4Health News:SNM honors outstanding contributors 5Health News:SNM honors outstanding contributors 6Health News:SNM honors outstanding contributors 7Health News:SNM honors outstanding contributors 8Health News:SNM honors outstanding contributors 9Health News:SNM honors outstanding contributors 10Health News:SNM honors outstanding contributors 11Health News:SNM honors outstanding contributors 12
Bechert-McPherson tying forceps, angled, 10 mm tying platforms....
Shepard tying forceps, round curved platform 8 mm, 8.5 cm....
Girard curved tying forceps made of titanium has curved shafts with 8 mm tying platforms, width of shafts 0,25 mm, TCI platforms, round handle, diam. 6 mm, overall length 99 mm....
Girard straight tying forceps made of titanium has straight shafts with 6 mm tying platforms, width of shafts 0,25 mm, TCI platforms, round handle, diam. 6 mm, overall length 105 mm....
Medicine Products: